


Clark Memorial Hospital
1220 Missouri Ave.
Jeffersonville, IN. 47130

February 5, 2007

To Whom It May Concern:

We would like to request an amendment to our license number 13-12367-01. We would like to add Thomas C. Passo M.D. , Naresh Solankhi M.D., and Naveen Devabhaktuni M.D. to our authorized user list limited to cardiovascular procedures. We also would like to add Mitchell Jay Kline M.D. for 10 CFR 35.100 and 35.200, Jerome Schrodt M.D. for 10 CFR 35.100,35.200 and 35.300(for iodine-131 use, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries), Richard Eickler M.D. for 10 CFR 35.100 and 35.200, Kevin P. Serey M.D. for 10 CFR 100, 35.200 and oral administration of sodium iodide-131 permitted by 35.300 and David P. Musich M.D. for 10 CFR 35.300 and materials listed in Subitems 6 D. and 6 E. of our current license. A copy of the current state and NRC licenses these physicians are on is enclosed.

Respectfully Yours,

A handwritten signature in black ink, appearing to read "Michael Tate". The signature is written in a cursive style and is positioned above the printed name of the signatory.

Michael Tate M.D.
Radiation Safety Officer

RECEIVED FEB 26 2007

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. St. Vincent Hospital & Health Care Center</p> <p>2. 2001 West 86th Street Indianapolis, IN 46240-0970</p>	<p>In accordance with letter dated July 28, 2005,</p> <p>3. License number 13-00133-02 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date July 31, 2012</p> <hr/> <p>5. Docket No. 030-01579 Reference No.</p>
---	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed 9 curies of iodine-131)
D. Any byproduct material permitted by 10 CFR 35.400	 <p>Sealed sources (Amersham M#s 1000, SI 20, SIAG, C-271, C-271, C-271, Nuclear Associates M#s 67-802, 67-803, 67-804, 67-801; 3M M#s 6D6C, Series 6500, 6520, 6510, 6570, 6550; North American Scientific M# MED3631AM; Theragenics M# 1031L, Bard Brachytherapy, Inc., Model STM 1251)</p>	D. As needed
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged kits	E. As needed
F. Iridium-192 permitted by 10 CFR 35.600	F. Sealed source (Nucletron Model 105.002 manufactured by Mallinckrodt Medical B.V. or AEA Technology, Inc.)	F. 4 sources not to exceed 13 curies each



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-00133-02

Docket or Reference Number
030-01579

Amendment No. 103

- Peter Nechay, M.D. 10 CFR 35.100 and 35.200, limited to cardiovascular clinical procedures.
- William E. McGraw, M.D. 10 CFR 35.100 and 35.200.
- Robert Curtis Oehler, M.D. 10 CFR 35.100 and 35.200, limited to cardiovascular clinical procedures.
- Cathy L. Clausen, M.D. 10 CFR 35.400, strontium-90 in the Novoste A1000 Series system, phosphorus-32 in the Guidant Galileo intravascular brachytherapy device and iridium-192 in remote afterloading brachytherapy unit.
- Chandrika Patel, M.D. 10 CFR 35.300, 35.400, iridium-192 in remote afterloading brachytherapy unit, and strontium-90 in the Novoste A1000 Series system.
- James M Scheffler, M.D. 10 CFR 35.200 limited to cardiovascular clinical procedures.
- Thomas P. Schleeter, M.D. 10 CFR 35.100 and 35.200 limited to cardiovascular clinical procedures.
- Ronald M. Razmi, M.D. 10 CFR 35.100 and 35.200 limited to cardiovascular clinical procedures.
- Daniel L. Ross, M.D. 10 CFR 35.300, 35.400, iridium-192 in remote afterloading brachytherapy unit, strontium-90 in the Novoste A1000 Series system, and phosphorus-32 in the Guidant Galileo intravascular brachytherapy device.
- David P. Musich, M.D.** 10 CFR 35.300, 35.400 and iridium-192 in remote afterloading brachytherapy unit.



C. The following individuals are authorized users for non-medical uses:

Authorized User

Material and Use

Edward Wroblewski

Subitem Nos. 6.I., 6.J. and 6.K.

William Breeden, III.

Subitem Nos. 6.I., 6.J. and 6.K.

NRC FGRM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 11 of 11 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License Number
13-00133-02

Docket or Reference Number
030-01579

Amendment No. 103

21. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated September 12, 2003; and
- B. Letters dated November 14, 2003, December 16, 2003, January 23, 2004, March 30, 2004, February 7, 2005, March 31, 2005, and April 7, 2005 (limited to authorization of package receipt area in security department), July 28, 2005; and
- C. Facsimile letter dated December 7, 2004 and two facsimiles dated September 16, 2005.



FOR U.S. NUCLEAR REGULATORY COMMISSION

Date OCT 11 2005

By James R. Mullauer
James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III

Official Use Only - Security-Related Information

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 1 PAGES
Amendment No. 41

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

02120

815787

Licensee

In accordance with letter dated

October 16, 2006,

1. Floyd Memorial Hospital

3. License number 13-12371-01 is amended in its entirety to read as follows:

2. 1850 State Street
New Albany, IN 47150

4. Expiration date April 30, 2014

5. Docket No. 030-01659

Reference No.

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

A. Any byproduct material permitted by 10 CFR 35.100

A. Any

As needed

B. Any byproduct material permitted by 10 CFR 35.200

B. Any

As needed

C. Any byproduct material permitted by 10 CFR 35.300

C. Any

As needed (not to exceed 1 curie of I-131)

D. Any byproduct material permitted by 10 CFR 35.400

D. Sealed sources (Bard Model STM1251; Theragenic Theraped Model 400; IsoRay Model CS-1)

D. 4 curies

E. Cesium-137

E. Sealed sources CIS-US, Inc. Model ORIS/CBI

E. 1900 curies, total

Official Use Only - Security-Related Information

1063190037

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 6 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-12371-01

Docket or Reference Number
030-01659

Amendment No. 41

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Manual brachytherapy use permitted by 10 CFR 35.400.
- E. To be used in a CIS-US Model IBL-437C self-contained irradiator for irradiation of Biologic Materials excluding flammable or explosive material.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 1850 State Street, New Albany, IN 47150.

11. The Radiation Safety Officer for this license is William R. Fortner, M.D.

12. Licensed material is only authorized for use under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized as authorized users as indicated:

Authorized Users

<u>Authorized Users</u>	<u>Material and Use</u>
William R. Fortner, M.D.	10 CFR 35.100, 35.200 and 35.300
Stephen J. Regan, M.D.	10 CFR 35.100, 35.200 and 35.300
Edsel S. Reed, M.D.	10 CFR 35.100, 35.200 and 35.300
Anthony Duncan, M.D.	10 CFR 35.100, 35.200 and 35.300
Bapineedu Gondi, M.D.	10 CFR 35.100 and 35.200
Carl E. Dillman, Jr., M.D.	10 CFR 35.100 and 35.200

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 6 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-12371-01

Docket or Reference Number
030-01659

Amendment No. 41

- | | |
|---------------------------------|---|
| Mohammed Hussain, M.D. | 10 CFR 35.100 and 35.200 |
| D. Mark Bickers, M.D. | 10 CFR 35.100 and 35.200 |
| Kelly J. Colomb, M.D. | 10 CFR 35.100, 35.200 and 35.300 |
| David R. Cannon, M.D. | 10 CFR 35.100 and 35.200 |
| David E. Stapp, M.D. | Subitem 6.E. |
| Craig S. Kamen, M.D. | 10 CFR 35.100, 35.200 and 35.300 |
| Michael M. Tate, M.D. | 10 CFR 35.100, 35.200 and 35.300 |
| Brian Worm, M.D. | 10 CFR 35.100, 35.200 and 35.300 |
| Srinivasarao Manchalapudi, M.D. | 10 CFR 35.100 and 35.200 |
| Kendall Goldschmidt, M.D. | 10 CFR 35.100, 35.200 and 35.300 |
| Dolph Martel Denny, M.D. | 10 CFR 35.100 |
| Christopher J. Day, M.D. | 10 CFR 35.100, 35.200 and 35.300 (for iodine-131 use, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries). |
| Mitchell Jay Kline, M.D. | 10 CFR 35.100 and 35.200 |
| Baby O. Jose, M.D. | 10 CFR 35.400 |
| Jerome Schrodt, M.D. | 10 CFR 35.100, 35.200 and oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries. |
| Richard Eickler, M.D. | 10 CFR 35.100 and 35.200 |
| Kevin P. Serey, M.D. | 10 CFR 35.100, 35.200 and oral administration of sodium iodide-131 permitted by 35.300. |

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 6 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-12371-01

Docket or Reference Number
030-01659

Amendment No. 41

- Naveen Devabhaktuni, M.D.** **10 CFR 35.200**
- Satya Garimella, M.D.** **10 CFR 35.200**
- Syed Raza, M.D.** **10 CFR 35.200**
- Anil K. Sharma, M.D.** **10 CFR 35.200**
- Mio Michael Stikovac, M.D.** **10 CFR 35.200**

13. For sealed sources not associated with 10 CFR Part 35 use the following 6 conditions apply:

- A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.
- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.
- C. In the absence of a certificate from a person controlling that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
- D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 5 of 6 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-12371-01

Docket or Reference Number
030-01659

Amendment No. 41

F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U. S. Nuclear Regulatory Commission or an Agreement State to perform such services.

14. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.
15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license.
16. The licensee shall not repair, remove, replace or alter any of the following: electrical and mechanical systems that control source or shielding movement, the irradiator's shielding or sealed source, safety interlocks, or any component that may affect safe operation of the irradiator. These activities shall be performed by a person specifically licensed by the Commission or an Agreement State to perform such services.
17. Except for maintaining labeling as required by 10 CFR Part 20 or 71, the licensee shall obtain authorization from the U.S. Nuclear Regulatory Commission before making any changes in the sealed source, device, or source-device combination that would alter the description or specifications as indicated in the respective Registered Certificate issued either by the Commission pursuant to 10 CFR 32.210 or by an Agreement State.
18. The procedures contained in manufacturer's instruction manual for the Model IBL-437C device shall be followed and a copy of this manual shall be made available to each person using or having responsibility for the use of the device.
19. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
20. In addition to the possession limits in Item 6, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 6 of 6 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET


License Number
13-12371-01

Docket or Reference Number
030-01659

Amendment No. 41

21. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated September 18, 2003; and,
- B. Facsimiles dated April 1, 2004, April 9, 2004, April 14, 2004; and
- C. Letters dated November 26, 2005 (with attached sketches), October 16, 2006; and
- D. Facsimile received February 17, 2006 (with attached sketch)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date NOV 13 2006

By James R. Mullauer
James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III

Official Use Only - Security-Related Information

CABINET FOR HEALTH SERVICES
COMMONWEALTH OF KENTUCKY
RADIOACTIVE MATERIAL LICENSE

PAGE 1

1. LICENSEE AND 2. ADDRESS

MEDICAL CENTER CARDIOLOGISTS
400 EXECUTIVE PK
LOUISVILLE, KY 40207

ATTENTION: JESSE E. ADAMS, M.D.
TELEPHONE: 502-585-4321

PURSUANT TO KRS 211.842 ET SEQ., THE KENTUCKY CABINET FOR HUMAN RESOURCES REGULATIONS, 902 KAR 100, AND IN RELIANCE ON STATEMENTS AND REPRESENTATIONS HERETOFORE MADE BY THE LICENSEE, A LICENSE IS HEREBY ISSUED TO RECEIVE, ACQUIRE, OWN, POSSESS AND TRANSFER RADIOACTIVE MATERIAL LISTED BELOW; AND TO USE SUCH RADIOACTIVE MATERIAL FOR THE PURPOSE(S) AND AT THE PLACE(S) DESIGNATED BELOW. THIS LICENSE IS SUBJECT TO ALL APPLICABLE RULES, REGULATIONS, AND ORDERS OF THE CABINET FOR HEALTH SERVICES, NOW OR HEREINAFTER IN EFFECT AND TO ANY CONDITIONS SPECIFIED BELOW.

3. LICENSE NUMBER: 202-233-24
AMENDMENT NO. 26
AMENDS IN ITS ENTIRETY

4. EXPIRATION DATE: OCTOBER 31, 2007

5. REVIEWER: 51

6. LICENSED MATERIAL 7. FORM 8. POSSESSION LIMIT
A. ANY RADIOACTIVE MATERIAL IDENTIFIED IN 902 KAR 100:072, SECTIONS 30 AND 31 A. ANY A. AS NECESSARY

CABINET FOR HEALTH SERVICES
COMMONWEALTH OF KENTUCKY
RADIOACTIVE MATERIAL LICENSE

LICENSE NUMBER: 202-233-24

AMENDMENT 26

PAGE 2

9. AUTHORIZED USE

- A. USES AUTHORIZED BY 902 KAR 100:072, SECTIONS 30 AND 31 (FOR CARDIAC STUDIES ONLY).

CONDITIONS:

10. THE LICENSEE SHALL COMPLY WITH THE PROVISIONS OF THE KENTUCKY CABINET FOR HEALTH SERVICES ADMINISTRATIVE RADIATION REGULATIONS, 902 KAR 100.
11. RADIOACTIVE MATERIAL SHALL BE USED ONLY AT THE LICENSEE'S FACILITIES LOCATED AT:
- A. 225 ABRAHAM FLEKNER WAY, SUITE 305, LOUISVILLE, KY 40202
B. 118 PATRIOT DRIVE, SUITE 103, BARDSTOWN, KY 40004
C. LAKEVIEW BUILDING, 100 MALLARD CREEK ROAD, SUITE 150, LOUISVILLE, KENTUCKY 40207.
12. RADIOACTIVE MATERIAL SHALL BE USED BY, OR UNDER THE SUPERVISION OF:
- | | |
|----------------------------|-----------------------|
| MATTHEW BESSEN, M.D. | THOMAS C. PASSO, M.D. |
| KODUVATHARA L. JAMES, M.D. | NARESH SOLANKHI, M.D. |
| REBECCA M. MCFARLAND, M.D. | ZAKA UR RAHMAN, M.D. |
13. THE RADIATION SAFETY OFFICER FOR THE ACTIVITIES AUTHORIZED BY THIS LICENSE IS MATTHEW BESSEN, M.D.
14. SEALED SOURCES CONTAINING RADIOACTIVE MATERIAL SHALL NOT BE OPENED.
15. EXCEPT AS OTHERWISE SPECIFIED BY LICENSE CONDITION, RECORDS MAINTAINED PURSUANT TO KENTUCKY ADMINISTRATIVE REGULATIONS 902 KAR 100 MAY BE DISPOSED OF AFTER A PERIOD OF FIVE (5) YEARS OF THE RECORDED EVENT EXCEPT RECORDS OF RECEIPT, TRANSFER AND DISPOSAL OF RADIOACTIVE MATERIAL SHALL BE MAINTAINED IN ACCORDANCE WITH 902 KAR 100:040, SECTION 15 AND 902 KAR 100:072, SECTION 29. RECORDS OF PERSONNEL MONITORING SHALL BE MAINTAINED UNTIL DISPOSAL IS AUTHORIZED BY THE CABINET.
16. EXCEPT AS SPECIFICALLY PROVIDED OTHERWISE IN THIS LICENSE, THE LICENSEE SHALL CONDUCT ITS PROGRAM IN ACCORDANCE WITH THE STATEMENTS, REPRESENTATIONS, AND PROCEDURES CONTAINED IN THE DOCUMENTS, INCLUDING ANY ENCLOSURES, LISTED BELOW. THE CABINET FOR HEALTH SERVICES REGULATIONS, 902 KAR 100, SHALL GOVERN UNLESS STATEMENTS, REPRESENTATIONS, AND PROCEDURES IN THE LICENSEE'S APPLICATION AND CORRESPONDENCE ARE MORE RESTRICTIVE

CABINET FOR HEALTH SERVICES
COMMONWEALTH OF KENTUCKY
RADIOACTIVE MATERIAL LICENSE


LICENSE NUMBER: 202-233-24

AMENDMENT 26

PAGE 3

THAN THE REGULATION.

- A. APPLICATION DATED AUGUST 21, 2006, SIGNED BY ROBERT P. ANDEREGG, PRACTICE ADMINISTRATOR.



MANAGER
RADIATION HEALTH BRANCH

MARK D. BIRDWHISTELL

SECRETARY
CABINET FOR HEALTH AND FAMILY
SERVICES

DATE ISSUED JANUARY 23, 2007

Clark Memorial Hospital
Nuclear Medicine
1220 Missouri Ave,
Jeffersonville, In. 47130

CERTIFIED MAIL™



7006 0810 0005 6163 5309



0000



60532

U.S. POSTAGE
PAID
JEFFERSONVILLE, IN
47130
FEB 21, 07
AMOUNT

\$5.12
00064026-06

**RETURN RECEIPT
REQUESTED**

United States Nuclear Regulatory Commission
Material Licensing Branch
Region III
2443 Warrenville Road
Lisle, Illinois
60532-4352

**RETURN RECEIPT
REQUESTED**

